The U.S. Securities and Exchange Commission today announced that AbbVie Pharmaceuticals, Inc. ("AbbVie"), a biopharmaceutical company based in New York City, has agreed to pay over $1 billion to acquire a clinical trial of its anti-inflammatory drug, RINVOQ.  The SEC's complaint, filed in federal court in Manhattan, alleges that AbbVie violated the antifraud provisions of the federal securities laws by failing to disclose that RINVOQ is a monoclonal antibody that targets specific targets in the specific areas of the face. The SEC alleges that RINVOQ is a subcutaneous administration of what is called Levodopa, which is a subcutaneous administration of what is known as Levodopa. The SEC alleges that Levodopa is a subcutaneous administration of a subcutaneous administration of what is called "Levodopa," which is a subcutaneous administration of levodopa. The U.S. Attorney's Office for the District of New York today announced criminal charges against RINVOQ. The SEC's complaint charges AbbVie with violating the antifraud provisions of Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. The SEC is seeking a final judgment on whether or not to proceed with the litigation. The SEC's investigation was conducted by Navin Amber and supervised by Marc Blau. The litigation will be led by Katherine Severino. The SEC appreciates the assistance of the U.S. Attorney's Office for New York and the Federal Bureau of Investigation.